Akero Therapeutics
General Information | |
Business: |
We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Our initial focus is on nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. NASH is a leading cause for liver transplantation. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 8 |
Founded: | 2017 |
Contact Information | |
Address | 170 Harbor Way, 3rd Floor, South San Francisco, CA 94080, US |
Phone Number | (650)-487-6488 |
Web Address | http://www.akerotx.com |
View Prospectus: | Akero Therapeutics |
Financial Information | |
Market Cap | $432.7mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-87.2 mil (last 12 months) |
IPO Profile | |
Symbol | AKRO |
Exchange | NASDAQ |
Shares (millions): | 5.8 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $92.0 mil |
Manager / Joint Managers | J.P. Morgan/ Jefferies/ Evercore ISI |
CO-Managers | Roth Capital Partners |
Expected To Trade: | 6/20/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |